Tuesday, October 17, 2017 9:32:57 AM
The data, although in only 1 patient, suggest that the drug may have a rapid impact on both the local tumour lesion and the innate and adaptive immune response, suggesting that monotherapy is likely quite active in SS/CTCL. Although most of the systematic immune cell changes were transient, it may be due to the transient systematic PK profile of a single local injection of the drug with a half-life of around 4 days, which however could be improved with repeated injections. Moreover, the impact on both innate and adaptive immune cells seen after it was administered indicates promising combination opportunities with other immunotherapies in CTCL, as evidenced by the likely synergistic effects seen with PEG-IFNa2a in this SS patient.''
Here is the PR from Trillium http://trilliumtherapeutics.com/investors/news/Press-Release-Details/2017/Trillium-Therapeutics-TTI-621-Program-Featured-at-the-EORTC-CLTF-Cutaneous-Lymphoma-Conference/default.aspx
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM